Medistim (MEDI)

[tooeasy891]

Danske øker kursmål til 260kr.

We expect a solid follow-up to impressive Q1 results

Medistim delivered impressive Q1 results that showed the company’s business areas firing on all cylinders. For Q2, we expect the core ultrasound business to continue to post strong organic growth but expect a more normalised quarter for the third-party distribution business. We are looking for reported group sales growth of 12% y/y (14% organic) and an EBIT margin of 25%.

• Breaking down the expectations. We highlight that it’s especially tricky to estimate Medistim sales on a quarterly basis as the ultrasound business, including consumables sales (aftermarket), is highly dependent on the placement of MiraQ systems in the short term. We expect a total of 58 systems to have been sold in the quarter, up c.14% y/y but down 8% versus Q1. In terms of consumables, we are expecting Medistim to deliver c.12% y/y growth, driven by volumes and mix.
• Third-party sales After a very strong start to the year, where Medistim reported third-party sales growth of 41% y/y, driven by one-off orders to a large hospital in Norway, we expect a more balanced Q2 print with sales growing 3% y/y. Over time, we believe it’s plausible for Medistim to grow its third-party business by mid-single-digits.
• Estimate changes. We make minor estimate changes, mainly due to FX movements.
• Valuation. We value Medistim based on multiples. An EV of 24x (previously 23x) 2026E EBIT on our estimates – a 10% discount to its 10-year EV/EBIT average and c.25% discount to peers – yields a 12M target price of NOK260 (NOK250).

[TekBot]

First half and second quarter results and financials for 2025 for Medistim ASA

Medistim invites you to a presentation of the first half and second quarter results and
financials for 2025 and status for the company. The results and financials will be presented through a webinar. The webinar takes place Wednesday the 20th of August 2025 and will start at 09.00 Norwegian time. The webinar will be available on Medistim website after the presentation.

…

Vis børsmeldingen

Representatives for the company will be:
Kari Eian Krogstad – CEO
Thomas Jakobsen - CFO

To sign up to join the
webinar please follow the link to register:
https://bit.ly/MedistimQ2andH12025Presentation

Kilde

[TekBot]

Financial results for the second quarter and first half of 2025 for Medistim ASA

Another strong quarter for sales revenues with 16.7 % growth, ending at MNOK 169.1 (MNOK 144.9). Record sales revenue for the first half year with 25.8 % growth, ending at MNOK 350.6 (MNOK 278.7).

Currency neutral sales of own products were up 18.7 % for the quarter and 25.4 % for the first half.
…

Vis børsmeldingen

Strong currency neutral growth for the quarter in AMERICAS and APAC, up 32.9 % and 22.9 % respectively. EMEA down 3.6 %, yet growing 8.1% in the first half.

Third-party distributor sales in Scandinavia increased 3.3 % for the quarter and 21.4 % for the first half year.

Operating profit (EBIT) grew by 31.2 % for the quarter and ended at MNOK 54.1, resulting in 32.0 % EBIT margin (MNOK 41.2, 28.5 % margin). First half operating profit grew 54.5 % ending at a record MNOK 113.3, and 32.3 % EBIT margin (MNOK 73.3, 26.3 % margin).

Recurring sales remained high, but strong capital sales reduce recurring sales in % to 66.8% (74.1 %) compared to the first half last year.

Medistim strengthened its commercial operation by appointing a Chief Commercial Officer and a new VP Sales for AMERICAS.

Solid cash position at quarter end with MNOK 96.4 after paying a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.9 in May (MNOK 82.4). No interest-bearing bank loans.

Kilde

[Savepig]

Woho, som de sier

[TekBot]

Major shareholder disclosure

We hereby declare that Danske Bank Group as of September 11th reached below 5% of threshold in Medistim ASA. Total aggregated holding is 895 181 corresponding to 4.88 % of the total voting rights. Ownership consists of: Danske Invest Engros corresponding to 0,38%, Danske Invest corresponding to 0,22%, Kapitalforeningen Danske Invest Institutional corresponding to 2,64%, Finnish Fund corresponding to 0,30%, SICAV corresponding to 0,39%, Danske Fund Luxembourg corresponding to 0,95%.
…

Vis børsmeldingen

Kilde

[TekBot]

Third quarter and year-to-date September results and financials for 2025 for Medistim ASA

Medistim invites you to a presentation of the third quarter and year-to-date September results and financials for 2025 and status for the company. The results and financials will be presented through a webinar. The webinar takes place Friday the 24th of October 2025 and will start at 09.00 Norwegian time. The webinar will be available on Medistim website after the presentation.

Representatives for the company will be:
…

Vis børsmeldingen

Kari Eian Krogstad – CEO
Thomas Jakobsen - CFO

To sign up to join the
webinar please follow the link to register:
https://bit.ly/MedistimQ3Results2025

Kilde

[tooeasy891]

[Savepig]

Voksent!

[Cardio]

Forklar gjerne for uinnvidde😅

[Savepig]

@tooeasy891 nevnte at det gikk en veldig stor enkelttransaksjon nylig:

På chartet jeg postet finner du igjen hvor mange aksjer det var i omsetning ift hva som har vært vanlig i det siste:

I teknisk analyse betyr en slik plutselig volumøkning at noen har gjort en ekte allokering i aksjen , det tolkes det som at bevegelsen har substans , at det ikke bare er småsparere eller roboter som dytter kursen tilfeldig.

Så det neste blir da å sjekke på aksjonærlistene om vi kan se noen interessante endringer på topp 50 ut i fra det.

[Savepig]

Boom:

[TekBot]

Financial results for the third quarter and YTD September 2025 for Medistim ASA

Another strong quarter for sales revenues with 25.7 % growth, ending at MNOK 166.8 (MNOK 132.8). Record sales revenue year to date September with 25.8 % growth, ending at MNOK 517.5 (MNOK 411.5). Currency neutral sales of own products were up 29.8 % for the quarter and 28.0 % year to date September.

Strong currency neutral growth for the quarter in AMERICAS and APAC, up 35.7 % and 194 % respectively. EMEA down 11.8 %, yet up 1 % year to date September.
…

Vis børsmeldingen

Third-party distributor sales in Scandinavia increased 4.4 % for the quarter and 16.2 % year to date September.

Operating profit (EBIT) grew by 27.1 % for the quarter and ended at MNOK 40.6, resulting in 24.3 % EBIT margin (MNOK 31.9, 24.0 % margin). Year to date September profit grew 46.2 % ending at a record MNOK 153.9, and 29.7 % EBIT margin (MNOK 105.2, 25.6 % margin).

Recurring sales remained high, but strong capital sales reduce recurring sales in % to 69.3% (73.7 %) compared to YTD September last year.

Solid cash position at quarter end with MNOK 157.6 after paying a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.5 in May (MNOK 82.4). No interest-bearing

Kilde

[Savepig]

I heite medistim

[tooeasy891]

Danske: Buy TP 320kr

Americas firing on all cylinders

Medistim delivered yet another strong set of numbers in Q3. Again, Americas was the main growth engine with 35% y/y growth. Also, APAC contributed positively with 193% growth as demand rebounded. Medistim’s implemented price increases didn’t hurt volumes, and we remain positive on its ability to deliver strong growth going forward and continue to find the valuation undemanding. We maintain Buy and increase our 12M TP to NOK320 (NOK310).

• Impact on the investment case. Medistim beat our expectations on sales and EBIT with 11% and 9%, respectively. The beat was driven by the Americas and APAC, growing both system and consumables sales strongly. It is encouraging to see continued strong demand for the company’s imaging platform, from which Medistim earns c.2x more than from flow-only. Imaging system sales stood at c.50% of all new systems sold, vs current installed base share of c.25%. We note however that there is still room for system sales to rebound further, fuelling the long-term aftermarket, as we still estimate system volumes for FY26 to be c.10% below the 2022 peak. Despite price increases, the aftermarket continues to perform very strongly and consumables sales in the US grew 86% y/y and 30% for the group, showcasing how Medistim’s customers continue to increase their utilisation of the systems and have absorbed the price increases implemented in the quarter.
• Estimate changes. We make slight upwards revisions to our FY25-27 estimates driven by higher ASP across the own product portfolio.
• Valuation. We value Medistim based on multiples. We lift our 12M TP to NOK320 (NOK310). We value Medistim to 26x 2026E EBIT, in line with its 10-year EV/EBIT average and a c.20% discount to peers.

[Savepig]

Blir nok fint å være medistimaksjonær på mandag og

[tooeasy891]

[Do2Do]

Oslo (Infront TDN Direkt): DNB Carnegie oppgraderer anbefalingen sin på Medistim til kjøp fra hold, og øker kursmålet på aksjen til 310 kroner fra 270 kroner.